Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Molecular determinants of Ebola virus virulence in mice.

Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, Theriault S, Bray M, Feldmann H, Kawaoka Y.

PLoS Pathog. 2006 Jul;2(7):e73.

2.

The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.

Groseth A, Marzi A, Hoenen T, Herwig A, Gardner D, Becker S, Ebihara H, Feldmann H.

PLoS Pathog. 2012;8(8):e1002847. doi: 10.1371/journal.ppat.1002847.

3.

Genetic factors of Ebola virus virulence in guinea pigs.

Subbotina E, Dadaeva A, Kachko A, Chepurnov A.

Virus Res. 2010 Oct;153(1):121-33. doi: 10.1016/j.virusres.2010.07.015.

PMID:
20654661
4.

Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase.

García M, Cooper A, Shi W, Bornmann W, Carrion R, Kalman D, Nabel GJ.

Sci Transl Med. 2012 Feb 29;4(123):123ra24. doi: 10.1126/scitranslmed.3003500.

5.

VP24 is a molecular determinant of Ebola virus virulence in guinea pigs.

Mateo M, Carbonnelle C, Reynard O, Kolesnikova L, Nemirov K, Page A, Volchkova VA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1011-20. doi: 10.1093/infdis/jir338.

6.

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.

Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST.

Virology. 2005 Feb 5;332(1):20-7.

7.

Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection.

Cilloniz C, Ebihara H, Ni C, Neumann G, Korth MJ, Kelly SM, Kawaoka Y, Feldmann H, Katze MG.

J Virol. 2011 Sep;85(17):9060-8. doi: 10.1128/JVI.00659-11.

8.

Cathepsin B & L are not required for ebola virus replication.

Marzi A, Reinheckel T, Feldmann H.

PLoS Negl Trop Dis. 2012;6(12):e1923. doi: 10.1371/journal.pntd.0001923.

9.

Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain.

Marzi A, Feldmann F, Hanley PW, Scott DP, Günther S, Feldmann H.

Emerg Infect Dis. 2015 Oct;21(10):1777-83. doi: 10.3201/eid2110.150259.

10.

Importin-α7 Is Involved in the Formation of Ebola Virus Inclusion Bodies but Is Not Essential for Pathogenicity in Mice.

Gabriel G, Feldmann F, Reimer R, Thiele S, Fischer M, Hartmann E, Bader M, Ebihara H, Hoenen T, Feldmann H.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S316-21. doi: 10.1093/infdis/jiv240.

11.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I.

Lancet. 2010 May 29;375(9729):1896-905. doi: 10.1016/S0140-6736(10)60357-1.

PMID:
20511019
12.

Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.

Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L.

J Virol. 2015 Oct;89(19):9932-8. doi: 10.1128/JVI.01337-15.

13.

A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.

Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1275. doi: 10.1371/journal.pntd.0001275.

14.

Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.

Kash JC, Mühlberger E, Carter V, Grosch M, Perwitasari O, Proll SC, Thomas MJ, Weber F, Klenk HD, Katze MG.

J Virol. 2006 Mar;80(6):3009-20.

15.

Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).

Morikawa S, Saijo M, Kurane I.

Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):391-8. Review.

PMID:
17610952
16.

Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.

Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94. doi: 10.1093/infdis/jiv215.

17.

RNA Editing of the GP Gene of Ebola Virus is an Important Pathogenicity Factor.

Volchkova VA, Dolnik O, Martinez MJ, Reynard O, Volchkov VE.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S226-33. doi: 10.1093/infdis/jiv309.

18.

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever.

Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, Saijo M, Feldmann F, Brining D, Feldmann H, Takada A.

PLoS One. 2012;7(4):e36192. doi: 10.1371/journal.pone.0036192.

20.

Antiviral activity of a small-molecule inhibitor of filovirus infection.

Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S.

Antimicrob Agents Chemother. 2010 May;54(5):2152-9. doi: 10.1128/AAC.01315-09.

Items per page

Supplemental Content

Support Center